If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-02. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
A Calutron is a sector mass spectrometer that was used for separating the isotopes of uranium developed by Ernest O. Lawrence during the Manhattan Project and was similar to the Cyclotron invented by Lawrence. Its name is a concatenation of Cal. U.-tron, in tribute to the University of California, Lawrence's institution and the contractor of the Los Alamos laboratory. They were implemented for industrial scale uranium enrichment at the Oak Ridge, Tennessee Y-12 plant established during the war and provided much of the uranium used for the "Little Boy" nuclear weapon, which was dropped onto Hiroshima in 1945.
There was concern about the possibility of arsenic from embalmed bodies contaminating ground water supplies, as well as legal concerns that people suspected of murder by arsenic poisoning might claim that levels of poison in the deceased's body were the result of post-mortem embalming, not homicide. In 1855, the Russian chemist Alexander Michailowitsch Butlerow discovered formaldehyde, the preservative properties of which were soon noted, and it became the foundation for modern methods of embalming. Dr Frederic Ruysch was the first to have used the arterial injection method for embalming. His work of embalming was so nearly perfect that people thought the dead body was actually alive; however, he only used it to prepare specimens for his anatomical work.
=== Lactation === The IGFR signalling pathway is of critical importance during normal development of mammary gland tissue during pregnancy and lactation. During pregnancy, there is intense proliferation of epithelial cells which form the duct and gland tissue. Following weaning, the cells undergo apoptosis and all the tissue is destroyed. Several growth factors and hormones are involved in this overall process, and IGF-1R is believed to have roles in the differentiation of the cells and a key role in inhibiting apoptosis until weaning is complete.
==== Microtubule-associated protein 2 ==== Similarly to pregnenolone, its synthetic derivative 3β-methoxypregnenolone (MAP-4343), and progesterone, DHEA has been found to bind to microtubule-associated protein 2 (MAP2), specifically the MAP2C subtype (Kd = 27 μM). However, it is unclear whether DHEA increases binding of MAP2 to tubulin like pregnenolone.
Sources: en.wikipedia.org
The sum of these two frequencies is the cyclotron frequency, which depends only on the ratio of electric charge to mass and on the strength of the magnetic field. This frequency can be measured very accurately and can be used to measure the masses of charged particles. Many of the highest-precision mass measurements (masses of the electron, proton, 2H, 20Ne and 28Si) come from Penning traps. Buffer gas cooling, resistive cooling, and laser cooling are techniques to remove energy from ions in a Penning trap. Buffer gas cooling relies on collisions between the ions and neutral gas molecules that bring the ion energy closer to the energy of the gas molecules. In resistive cooling, moving image charges in the electrodes are made to do work through an external resistor, effectively removing energy from the ions. Laser cooling can be used to remove energy from some kinds of ions in Penning traps. This technique requires ions with an appropriate electronic structure. Radiative cooling is the process by which the ions lose energy by creating electromagnetic waves by virtue of their acceleration in the magnetic field. This process dominates the cooling of electrons in Penning traps, but is very small and usually negligible for heavier particles. Using the Penning trap can have advantages over the radio frequency trap (Paul trap). Firstly, in the Penning trap only static fields are applied and therefore there is no micro-motion and resultant heating of the ions due to the dynamic fields, even for extended 2- and 3-dimensional ion Coulomb crystals.
LG CNS Co., Ltd. (Korean: 주식회사 엘지씨엔에스) is a South Korean technology company offering services in artificial intelligence, robotics, cloud computing, smart factories, smart logistics, system integration, and IT Outsourcing (ITO).
India is a federal union comprising 28 states and 8 union territories. All states, as well as the union territories of Jammu and Kashmir, Puducherry and the National Capital Territory of Delhi, have elected legislatures and governments following the Westminster system. The remaining five union territories are directly ruled by the central government through appointed administrators. In 1956, under the States Reorganisation Act, states were reorganised on a linguistic basis. Over a quarter of a million local government bodies operate at the city, town, district, block, and village levels.
=== Tumors === Th22 cells are involved in tumorigenesis in cases of hepatocellular carcinoma, liposarcoma or colon cancer, and affect tumor tissue in two different pathways. Overexpression of interleukin-22 (IL-22) or Th22 cells may result in the progression of cancer growth and cause malignant epithelial cell proliferation. However, physiological functions of Th22 cells are tissue repair and wound healing. Some studies have shown a possible anti-tumor effect of these cells, and normal interleukin-22 (IL-22) secretion leads to tissue repair.
=== Semi-chisel saw chains === The semi-chisel chain has teeth with rounded corners formed by a radius between the top and side plates. While slower than full chisel in softwood, it retains an acceptable cutting sharpness longer, making it the preferred choice for dirtier wood, hard or dry wood, frozen wood or stump work, all of which would rapidly degrade full chisel chain. They are similar to the full chisel design but have a small 45 degree chamfer between the plates rather than a radius. Performance is similar to full chisel. Semi chisel chains have a lower kick-back risk. These chains are available for consumer, semi-pro and professional saws.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.